Affiliations: [a] Medical Oncology, St. Salvatore Hospital, L’Aquila, Italy | [b] Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy
Correspondence:
[*]
Corresponding author: Francesco Pavese, MD, Medical Oncology Unit, St. Salvatore Hospital, L’Aquila, Italy; and Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Via Vetoio, 67100, L’Aquila, Italy. Tel.: +39 08 62368709; Fax: +39 08 62368682; E-mail: francesco.pavese@outlook.it
Abstract: BACKGROUND:Despite the increase in chances of cure for early breast cancer (EBC) patients, approximately 20–45% of them will experience a disease recurrence, particularly bone metastases in 60–80% of cases, which occur more frequently in luminal subtypes. Endocrine therapy (ET) has always been the milestone of adjuvant treatment for hormone receptor-positive EBC patients, leading to indubitable reduction of disease recurrence risk. However, adjuvant aromatase inhibitors (AIs) therapy may promote a progressive decrease in bone mineral density (BMD), which can lead to osteoporosis. The increased bone resorption associated with osteoporosis may provide fertile soil for cancer growth and accelerate the development of bone metastases. PATIENTS AND METHODS:In this single-institution cohort study, we performed a retrospective analysis of “luminal-like” EBC patients who experienced bone recurrence after a subsequent disease free interval. The aim of the study was to evaluate the median time to skeletal recurrence (TSkR). RESULTS:143 patients experienced bone recurrence. Median TSkR was 54 months (95%CI: 45–65). Among patients who received adjuvant AIs median TSkR was 35 months (95%CI: 25–54), while among patients who did not was 61 months (95%CI: 50–80) (HR = 1.45 [95%CI: 0.97–2.17], p = 0.0644). After adjusting for TNM stage (AJCC 8th edition), adjuvant AIs treatment was significantly related to a shorter TSkR (HR = 1.60 [95%CI: 1.06–2.42], p = 0.0244). Adjuvant Tamoxifen, adjuvant AIs/Tamoxifen and no-treatment did not revealed to be associated to TSkR. CONCLUSIONS:In this cohort of EBC patients with bone recurrence, AIs treatment seems to be related to a shorter TSkR. AIs-induced bone resorption might represent the underlying mechanism.
Keywords: Bone relapse, osteoporosis, breast cancer, endocrine therapy, aromatase inhibitors, bone resorption, skeletal metastases
DOI: 10.3233/BD-201036
Journal: Breast Disease, vol. 40, no. 4, pp. 257-262, 2021
